Avidity Biosciences, Inc.

About Avidity Biosciences, Inc.

Avidity Biosciences is dedicated to improving people's lives by developing a new class of targeted RNA therapeutics through their innovative Antibody Oligonucleotide Conjugates (AOC™) platform. They focus on addressing the root causes of diseases, starting with muscle disease treatments, and aim to expand into other therapeutic areas to meet unmet patient needs.

Products & Services

Antibody Oligonucleotide Conjugates (AOC™) Platform:A technology combining monoclonal antibodies and oligonucleotides to target previously inaccessible tissues and cells, addressing the genetic drivers of diseases.

Myotonic Dystrophy Type 1 (DM1) Program:A therapeutic program targeting the root cause of myotonic dystrophy type 1, a rare muscle disease.

Facioscapulohumeral Muscular Dystrophy (FSHD) Program:A treatment program focused on facioscapulohumeral muscular dystrophy, addressing underlying genetic issues.

Duchenne Muscular Dystrophy (DMD) Program:A therapeutic initiative for Duchenne muscular dystrophy, targeting the genetic basis of the disease.

Precision Cardiology Program:A program aimed at developing targeted treatments for cardiac conditions using the AOC platform.

Specialties

RNA Therapeutics Antibody Oligonucleotide Conjugates (AOC™) Rare Muscle Diseases Precision Cardiology

Funding History

No funding data available

This company may be bootstrapped or privately funded

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Troy Wilson

Board Chair and Co-Founder, Avidity Biosciences; Chief Executive Officer and Director, Kura Oncology

C

Carsten Boess

Board Member

N

Noreen Roth Henig

Board Member

J

Jean Kim

Board Member

E

Edward Kaye

Board Member

S

Simona Skerjanec

Board Member

View 15 more team members with Pro

Unlock Full Team Directory

Recent News